4.2Р31.4Р1.32 (1.05, 1.65)РP = 0.01РBIOLOGICРSIDE OF PRIMARYРHR?95% CIРP (adjusted*)РAny biologic?OS and PFSРCet v Bev; left? Cet Bev; rightР1.53?(1.13, 2.08)РPint = 0.005РCet v Bev?OSРLeftР0.82?(0.69, 0.96)Рp = 0.01РPFSР0.84?(0.72, 0.98)РCet v Bev?OSРRightР1.26?(0.98, 1.63)Рp = 0.08РPFSР1.26?(1.00, 1.62)Р*Adjusted for biologic, protocol chemotherapy, prior adjuvant therapy, prior RT, age, sex, synchronous disease, in place primary, liver metastasesР结论:野生型患者无论何种治疗方式,左半比右半有更好的OSР结论:西妥昔单抗和贝伐珠单抗一线治疗在左右半中有不同的疗效РVenook AP, et al. 2016 ASCO Abstract 3504Р右半结肠mCRC长期生存: ?三项临床研究显示贝伐珠单抗较西妥昔单抗OS数值更高РHR=1.26Рn=79Рn=39Рn=30Рn=43Рn=150Рn=143РP=0.08Р1,Heinemann V, et al. Presented at: ASCO. 2014 (abstr 3600).?2,Venook AP, et al. 2016 ASCO Abstract 3504?3, Houts A, et al. Poster. ASCO GI. 2016 (abstr 550)
全文预览
